SYDNEY, Aus. & ST. LOUIS--(BUSINESS WIRE)--NewSouth Innovations Pty Limited, the technology transfer arm of University of New South Wales (UNSW), and Covidien Ltd. (NYSE: COV, BSX: COV) today announced the signing of a license agreement to develop an innovative, radiolabeled molecular imaging agent for evaluating the efficacy of cancer treatments. This technology could assist oncologists in determining the effectiveness of treatment and the necessity for other therapeutic measures.
